Holen Sie sich die Stockscreener-App
22.33
1.18%
0.31
Handel nachbörslich:
22.33
Schlusskurs vom Vortag:
$22.02
Offen:
$22.44
24-Stunden-Volumen:
665.95K
Relative Volume:
0.52
Marktkapitalisierung:
$2.85B
Einnahmen:
$24.05M
Nettoeinkommen (Verlust:
$-243.33M
KGV:
-7.4423
EPS:
-3.0004
Netto-Cashflow:
$-370.18M
1W Leistung:
+3.50%
1M Leistung:
-10.63%
6M Leistung:
+191.61%
1J Leistung:
+357.01%
1-Tages-Spanne:
$21.73
$22.56
1-Wochen-Bereich:
$21.20
$22.72
52-Wochen-Spanne:
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
22.33 | 2.81B | 24.05M | -243.33M | -370.18M | -3.0004 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-25 | Eingeleitet | Stifel | Buy |
| 2026-01-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors - simplywall.st
Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS - Benzinga
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model? - Yahoo Finance
Chardan Capital Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $40 - Moomoo
ALMS Maintained by Chardan Capital -- Price Target Raised to $40 - GuruFocus
Alumis price target raised to $40 from $38 at Chardan - TipRanks
Chardan Raises Price Target on Alumis to $40 From $38, Keeps Buy Rating - marketscreener.com
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Data And Upcoming Regulatory Milestones - Sahm
This Alumis analyst is no longer bullish; here are top 5 downgrades for Friday - MSN
ALUMIS INC. ($ALMS) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] ALUMIS INC. SEC Filing - Stock Titan
[DEF 14A] ALUMIS INC. Definitive Proxy Statement - Stock Titan
Cormorant Asset Management Acquires 313,645 Shares of Alumis in Q1 2026 - IndexBox
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - The Motley Fool
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - The Motley Fool
Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors? - Sahm
Alumis’ Envudeucitinib Hits 68% PASI 90 in Phase 3 Psoriasis Trial - The Clinical Trial Vanguard
HC Wainwright & Co. downgrades Alumis (ALMS) - MSN
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back - AOL.com
Morgan Stanley Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $39 - Moomoo
All News about Alumis Inc.Common Stock - The Chronicle-Journal
ALMS Maintained by Guggenheim -- Price Target Raised to $34 - GuruFocus
ALMS Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Aardvark’s next move after clinical hold; Alumis’ verdict on Acelyrin asset - Endpoints News
Stifel reiterates Alumis stock rating on psoriasis trial data By Investing.com - Investing.com South Africa
Stifel reiterates Alumis stock rating on psoriasis trial data - Investing.com
Why Alumis Inc. Stock Is Sliding After Good News - TipRanks
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
H.C. Wainwright Downgrades Alumis(ALMS.US) to Hold Rating, Maintains Target Price $25 - Moomoo
Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $51 - Moomoo
Guggenheim raises Alumis stock price target to $34 on psoriasis data By Investing.com - Investing.com South Africa
Guggenheim raises Alumis stock price target to $34 on psoriasis data - Investing.com
Alumis Q1 Loss Narrows, Revenue Falls; Shares Down Pre-Bell - marketscreener.com
HC Wainwright Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects - Fierce Biotech
Alumis (ALMS) Reports Q1 Earnings with Focus on Psoriasis Treatm - GuruFocus
ALMS SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
A Look At Alumis (ALMS) Valuation After Revenue Drop And Narrowed Net Loss - Yahoo Finance
ALMS Financials: Income Statement, Balance Sheet & Cash Flow | Alumis Inc - Stock Titan
Alumis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
[10-Q] ALUMIS INC. Quarterly Earnings Report - Stock Titan
Q1 2026 earnings and future milestones announced by ALUMIS INC. - Traders Union
Alumis Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Envudeucitinib Phase 3 gains and Q1 2026 results for Alumis (NASDAQ: ALMS) - Stock Titan
Earnings Flash (ALMS) Alumis Inc. Reports Q1 Revenue $1.7M, vs. FactSet Est of $2.5M - marketscreener.com
Press Release: Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements - Moomoo
Alumis psoriasis pill hits 68% PASI 90 in Phase 3 trial - Stock Titan
ALUMIS INC. to present new biomarker data on investigational PsO treatment at Chicago conference - Traders Union
TradingKey - TradingKey
ALMS Stock Price, Quote & Chart | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug - AOL.com
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alumis Inc-Aktie (ALMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Foresite Labs, LLC | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Foresite Capital Management VI | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Tananbaum James B. | Director |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| AKKARAJU SRINIVAS | Director |
Dec 05 '25 |
Buy |
9.84 |
186,377 |
1,833,760 |
1,265,253 |
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):